Several UK outlets report that patients treated with a new NHS “immune reset” therapy have gone into remission. The treatment is described as genetically modifying a patient’s cells so that the body’s own immune system can better recognise and attack problematic cells. The coverage links the approach to immune-based remission outcomes, with one report specifically citing lupus patients achieving remission following the therapy.
Across the articles, the central mechanism is consistent: the therapy involves engineering cells to change immune targeting, enabling the immune system to respond more effectively against disease-related cells. The reports frame the results as significant clinical progress, but they do not provide detailed figures, timelines, or comparative outcomes in the excerpts provided.
Taken together, the sources indicate that the NHS is delivering this genetic immune therapy and that at least some treated patients are reaching remission, including cases reported for lupus. Further details on eligibility criteria, number of participants, duration of remission, and long-term safety are not included in the supplied summaries.
